Agendia Announces Definitive Mandatory Swiss Health Insurance Reimbursement for MammaPrint

Effective 1 July 2026, Switzerland’s FOPH completed its review of multigene expression testing and decided to continue reimbursement indefinitely. The decision reduces payer uncertainty and supports ongoing coverage for the testing approach in Switzerland.

Analysis

Effective 1 July 2026, Switzerland’s FOPH completed its review of multigene expression testing and decided to continue reimbursement indefinitely. The decision reduces payer uncertainty and supports ongoing coverage for the testing approach in Switzerland.